2Barradell LB,Fanlds D, Mctavish D.Lansoprazole: a review of its pharmacodynamic and pharmacokinetic properties and its thera- peutic efficacy in acid 2 related disorders [J].Drugs,2012,44(2): 225-250.
3Moayyedi P,Cranney A.Hip fracture and proton pump inhibitor therapy:balancing the evidence for benefit and hram.Am J Gas- troenterol, 2008,103 : 2428-2431.
4Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors [J]. BMJ, 2008, 336(7634) : 2-3.
5Rotman SR, Bishop TF. Proton pump inhibitor use in the U. S. ambulatory setting, 2002-2009 [ J ]. PLoS One, 13,8 ( 2 ) : e56060.
6SAHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. SAHP commission on therapeutics and approved by the SAHP board of directors on Noveeberl4, 1998 [ J ]. Am J Health Syst Pharm, 1999, 56(4) : 347-379.
7Bhalt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus doeument on redueing the gastroingtestinal risks of antiplatelet therapy and NSAID Use: a report of the American College of Cardiology Foundation Task Foree on Clinieal Expert Consensus Documents [ J ]. J Am Coil Cardiol, 2008,52 (18) : 1502-1517.
8Yachimski P, Farrell E, Hunt D, et al. Proton pump inhibitors for prophylaxis of nosocomial upper gastrointestinal tract bleeding, effect of standard guidelines on prescribing practice[ J]. Arch Intern Med, 2010, 170(9) :779-783.
9Dial MS. Proton pump inhibitor use and enteric infections [ J ]. Am J Gastroenterol, 2009,104 ($2) : 10-16.
10Garcia Rodriguez LA, Ruigomez A, Panes J. Use of acid- suppressing drugs and the risk of bacterial gastroenteritis [ J ]. Clin Gastroenterol Hepatol, 2007,5 (12) : 1418-1423.
